MedTrace Logo

A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients

NCT06833853 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 187

Last updated 2026-03-18

No results posted yet for this study

Summary

The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Receptor 2 (HER2), Estrogen Receptor (ER), and programmed death-ligand 1 (PD-L1) and cell free DNA/RNA (cfDNA/RNA) analysis.

Conditions

  • Metastatic Breast Cancer (MBC)

Sponsors & Collaborators

  • Menarini Silicon Biosystems, INC

    lead INDUSTRY

Principal Investigators

  • Marija Balic, MD, PhD, MBA · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-13
Primary Completion
2028-10-31
Completion
2028-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06833853 on ClinicalTrials.gov